类风湿关节炎患者中环孢素A新口服剂型的相对生物利用度。
Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis.
作者信息
van den Borne B E, Landewé R B, Goei The H S, Mattie H, Breedveld F C, Dijkmans B A
机构信息
Department of Rheumatology, University Hospital, Leiden, The Netherlands.
出版信息
Br J Clin Pharmacol. 1995 Feb;39(2):172-5. doi: 10.1111/j.1365-2125.1995.tb04425.x.
The relative bioavailability of cyclosporin A (CsA) from a new microemulsion oral formulation (NEO) and the currently used soft gelatine capsule (SGC) was determined at steady state in 12 patients with rheumatoid arthritis. The AUC(0,12 h) values of cyclosporin A were significantly greater after NEO than SGC (2873 +/- 848 ng ml-1 h (mean +/- s.d.) vs 2355 +/- 1128 ng ml-1 h; P = 0.02, 95% CI (confidence interval of the difference: 81 to 955 ng ml-1 h). Cmax values were significantly higher after NEO than after SGC (811 +/- 244 ng ml-1 vs 495 +/- 291 ng ml-1, P < 0.0001, 95% CI of the difference: 209 to 422 ng ml-1).
在12例类风湿性关节炎患者中，以稳态测定了新的微乳口服制剂（NEO）和目前使用的软胶囊（SGC）中环孢素A（CsA）的相对生物利用度。环孢素A的AUC(0,12 h)值在服用NEO后显著高于SGC（2873±848 ng ml-1 h（平均值±标准差）对2355±1128 ng ml-1 h；P = 0.02，95%置信区间（差异的置信区间：81至955 ng ml-1 h）。NEO后的Cmax值显著高于SGC后（811±244 ng ml-1对495±291 ng ml-1，P < 0.0001，差异的95%置信区间：209至422 ng ml-1）。
Zotero 插件